A new treatment that eliminates the spread of breast cancer
In a promising scientific leap, the results of a large clinical trial showed that treating breast cancer using an innovative oral drug produced by AstraZeneca can reduce the risk of disease progression or death by up to 56%, if used at the first signs of the body’s resistance to traditional treatments.
This therapeutic advance, based on a simple blood analysis known as “liquid biopsy”, may constitute a radical shift in the way of dealing with one of the most common types of cancer among women around the world, and redraw the map of hope in humanity’s struggle with cancer.
At the American Society of Clinical Oncology conference, which was held recently in Chicago, a team of researchers presented these detailed findings, noting that relying on blood tests to detect resistance of cancer cells to treatment – before signs of growth appear on the scans – allowed for early therapeutic intervention. This new concept, which was called “early transformation,” simply means that doctors can be proactive in confronting the tumor, instead of reacting late after the condition worsens.
Dr. Eleonora Teplinsky – a specialist in oncology – explained that relying on radiology to detect the progress of the disease always makes us late in responding, noting that the liquid biopsy allowed doctors to make the decision to switch treatments before the disease actually developed, and although the new drug “Kamistrant” has not yet received approval from the US Food and Drug Administration, experts believe that these results will chart a new therapeutic path over the years. Upcoming.
Monitoring cancer resistance through blood analysis
The trial included about 3,256 patients suffering from hormone receptor-positive and HER2-negative breast cancer, which is the most common type, as estrogen fuels the growth of cancer cells. The participants received conventional hormone therapy for a period of at least six months, along with targeted medications known as CDK4/6 inhibitors, such as “Kizkali” from Novartis, “Ibrance” from Pfizer, and “Verzino” from Eli Lilly.
What is interesting about the study is that about 40% of these patients developed mutations in the estrogen receptor gene ESR1, which is an early indication of resistance to treatment, and here comes the role of “camistrant,” a drug from the category of “selective estrogen receptor inhibitors” (SERDs), which works to disrupt estrogen signals that fuel the growth of cancer cells, even in the presence of mutations that make other treatments less effective.
The real power of this development is that it reflects a shift from “reactive” to “proactive prevention,” which could significantly reduce the health, psychological, and economic burdens of cancer; When treatment resistance is detected before clinical symptoms or tumor development appear in examinations, months or years of suffering and complications can be avoided.
Sustainability in healthcare
The shift in medical thinking from “dealing with disease after its onset” to “preempting preventive treatment based on precise biological signals” not only reflects the maturity of medical research, but is consistent with the philosophy of the Sustainable Development Goals (SDGs), especially Goal (3) “good health and well-being”; Early diagnosis and immediate treatment techniques reduce the need for expensive treatments, relieve pressure on health care systems, and enhance the ability of societies to cope with the burden of chronic diseases such as cancer.
AstraZeneca CEO Pascal Soriot acknowledged that implementing this type of proactive follow-up would require a major change in doctors’ practices, but he stressed that this is the future of cancer treatment. In light of the rapid progress in artificial intelligence and precision medicine technologies, blood analysis to determine the turning point in cancer resistance will not remain limited to major hospitals, but may one day become part of routine examinations.
This new approach also contributes to achieving health equity, by reducing reliance on advanced imaging devices or expensive surgical operations, and providing early diagnostic tools that may be more applicable in low- and middle-income countries, which opens the way for the adoption of sustainable and integrated health strategies that ensure equitable access to care and treatment.
Promising results in stomach and esophageal cancers
AstraZeneca’s announcement was not limited to the breast cancer drug; The company also revealed promising results for its immunotherapy drug Imfinzi (Durvalumab), which has proven effective in delaying cancer recurrence or progression in patients with stomach and esophageal cancer in its early stages. A clinical trial that included about 950 patients around the world showed that using “Imfinzi,” in addition to traditional chemotherapy before and after surgery, helped reduce the risk of disease relapse by 29%, compared to relying on chemotherapy alone.
Dr. Yelena Janigian – from the Sloan Kettering Cancer Center in New York – described the results as historic, noting that demonstrating the effectiveness of immunotherapy in the early stages of cancer opens new horizons in dealing with these diseases, which are among the main causes of death globally.
Baheya Foundation, a support model for breast cancer patients
At a time when international pharmaceutical companies are leading the scene with promising innovations, concrete efforts are continuing at the local level in Egypt to combat cancer, especially breast cancer, where medical and community initiatives converge to provide a comprehensive environment for support and treatment, and one of the most prominent of these efforts is what is being done by the “Baheya” Foundation, which has become a pioneering model in providing integrated care, both physically and psychologically, for women with breast cancer.
In the “There is a Story” campaign, the Foundation’s efforts were not limited to spreading awareness only, but also delved into the depths of the stories of women who bravely fought the disease and turned the harsh experience into a source of inspiration and hope. These stories received great support from the stars of art in Egypt and the Arab world. Which contributed to breaking the silence around the disease, and pushed society towards accepting talk about the psychological and medical challenges associated with breast cancer.
This Egyptian model proves that combining medical progress with community inclusion is the key to achieving real and sustainable impact; Every awareness campaign or psychological support provided to a patient is a step towards reducing pressure on health care systems, improving the quality of life, and enabling women to overcome disease, in full accordance with the philosophy of sustainable development that upholds human value and his right to a healthy and dignified life.
In conclusion,Earth Guards believes that these rapid medical transformations pave the way for a new path in understanding and dealing with cancer, but at the same time they put health systems before a greater test. It is the ability of countries and societies to implement fair policies and flexible infrastructure that ensure widespread access to treatment and early diagnosis; Progress in itself is not an achievement, but rather the success of societies in transforming this progress into a right available to all.
